Repro Med Systems (KRMD) Tops Q4 EPS by 3c, provides guidance

Repro Med Systems (NASDAQ: KRMD) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $10.68 million.

GUIDANCE:

Repro Med Systems sees FY2026 revenue of $47.5-50 million, versus the consensus of $48.476 million, representing growth of 15% - 22%
Full year 2026 gross margin between 61 - 63%
Positive adjusted EBITDA and positive cash flow for the full year 2026

For earnings history and earnings-related data on Repro Med Systems (KRMD) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Brookfield offers A$4.75/sh for Reliance Worldwide - Bloomberg